Background: Neutrophils are central to the defence against infection; in newborns, production and function are immature. Intrauterine growth restriction increases the risk of both neutropenia and sepsis. We report clinical outcomes of a randomised controlled trial of prophylactic GM-CSF in babies born below 32 weeks gestation.
Subjects & interventions: Twenty five appropriately grown(AG) and 19 growth restricted (GR) infants have been randomised to date to receive recombinant granulocyte-macrophage colony stimulating factor (GM-CSF)(Leucomax, Sandoz), 10μg/kg daily, subcutaneously for 5 days, commencing within 72 hours of birth, or to a control group. Birthweight and gestational age, as median (range), were treatment (n=23) 1.1 kg (0.570,1.476) and 28 weeks (23,31); control (n=22) 0.920 (0.480,1.290) and 27 (24,30).
Results: There were no adverse effects attributable to GM-CSF; in particular, no difference in oxygen requirement at 36 weeks post menstrual age (p=0.34). No treated babies developed neutropenia in contrast to 8 (2 AG; 6 GR) in the control group (p=0.0015). Sepsis precipitated neutropenia in 3 control GR babies only. Though there was no significant difference in mortality from all causes, there were 3 deaths from sepsis in the control group and 1 in the treatment group. No AG infant died of sepsis.
Conclusions: Prophylactic treatment of preterm neonates with GM-CSF is safe, completely abolishes the postnatal neutropenia of GR babies and may decrease mortality from sepsis.
Author information
Authors and Affiliations
Additional information
Ann Opute1 (sponsored by David Harvey)
Rights and permissions
About this article
Cite this article
Modi, N., Carr, R., Lindo, D. et al. A Randomised Controlled Trial of Prophylactic Granulocyte-Macrophage Colony Stimulating Factor in Preterm Newborns. Pediatr Res 42, 400 (1997). https://doi.org/10.1203/00006450-199709000-00113
Issue Date:
DOI: https://doi.org/10.1203/00006450-199709000-00113